SCHEMBL869065

SCHEMBL869065

CC1CCCCCCCCCc2cc(O)cc(O)c2C(=O)O1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.88
SMN1; SMN2 Q16637 4/20 0.88
ESR2 Q92731 4/20 0.88
ALDH1A1 P00352 4/20 0.88
HSP90AA1 P07900 3/20 0.88
HSP90AB1 P08238 3/20 0.88
CYP3A4 P08684 3/20 0.88
NR1I2 O75469 1/20 0.88
TP53 P04637 1/20 0.88
POLB P06746 1/20 0.88
MAPT P10636 1/20 0.88
MKNK1 Q9BUB5 1/20 0.66
MKNK2 Q9HBH9 1/20 0.66
F13A1 P00488 1/20 0.62
TGM2 P21980 1/20 0.62
ACVRL1 P37023 4/20 0.59
FLT4 P35916 4/20 0.57
KDR P35968 4/20 0.57
FLT3 P36888 4/20 0.57
MAP2K2 P36507 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29737259 1.00 LMNA (0.88) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1
SCHEMBL31217635 1.00 LMNA (0.88) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1
SCHEMBL30163150 1.00 LMNA (0.88) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1
SCHEMBL20121859 0.95 LMNA (0.84) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1
Zeranol SCHEMBL2602612 0.94 LMNA (1.00) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1
Zeranol SCHEMBL9592548 0.94 LMNA (1.00) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1
Zeranol SCHEMBL109174 0.94 LMNA (1.00) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1
Zeranol SCHEMBL31122084 0.94 LMNA (1.00) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1
Zeranol SCHEMBL10773090 0.94 LMNA (1.00) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1
Zeranol SCHEMBL29554783 0.94 LMNA (1.00) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0251813-B1 IMMUNOSTIMULATING AGENTS IMCERA Group Inc. (US) 1993-06-23 EP claimed
EP-0299794-B1 RESORCYLIC ACID LACTONE COMPOUNDS FOR CONTROLLING HELMINTIC PARASITES IMCERA Group Inc. (US) 1993-02-03 EP claimed
US-4842862-A ZEARALANE AND DERIVATIVES INTERNATIONAL MINERALS & CHEMICAL CORP. (US) 1989-06-27 US claimed
EP-0299794-A2 Resorcylic acid lactone compounds for controlling helmintic parasites IMCERA Group Inc. (US) 1989-01-18 EP claimed
US-4778821-A ADMINISTERING RESORCYLIC ACID LACTONE INTERNATIONAL MINERALS & CHEMICAL CORP. (US) 1988-10-18 US claimed
EP-0251813-A2 Immunostimulating agents IMCERA Group Inc. (US) 1988-01-07 EP claimed
US-4088658-A REACTING HYDROXY COMPOUND WITH A SULFONYL CHLORIDE TO FORM SULFONATE, HYDROGENOLYSIS IMC CHEMICAL GROUP, INC. (US) 1978-05-09 US claimed
US-12455283-B2 Methods for screening polypeptides capable of binding specific target molecules and tools related thereto TEKNOLOGIAN TUTKIMUSKESKUS VTT OY (FI) 2025-10-28 US disclosed
US-10239856-B2 Synthesis of resorcylic acid lactones useful as therapeutic agents UNIVERSITY DE STRASBOURG (FR) 2019-03-26 US disclosed
EP-2136799-B1 MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 UNIV STRASBOURG (FR) 2017-10-04 EP disclosed
EP-2254880-B1 Macrocyclic prodrug compounds useful as therapeutics NEXGENIX PHARMACEUTICALS (US) 2016-08-17 EP disclosed
EP-2242359-B1 SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS UNIV STRASBOURG (FR) 2016-06-01 EP disclosed
CN-101990399-B Synthetic as the RALs of therapeutic agent UNIVERSITE DE STRASBOURG (FR) 2016-05-04 CN disclosed
EP-0251813-A2 Immunostimulating agents IMCERA Group Inc. (US) 1988-01-07 EP disclosed
EP-0251813-A2 Immunostimulating agents IMCERA Group Inc. (US) 1988-01-07 EP disclosed
US-4690948-A FEEDS RUMEN FERMENTATION EFFICIENCY INTERNATIONAL MINERALS & CHEMICAL CORP. (US) 1987-09-01 US disclosed
US-4088658-A REACTING HYDROXY COMPOUND WITH A SULFONYL CHLORIDE TO FORM SULFONATE, HYDROGENOLYSIS IMC CHEMICAL GROUP, INC. (US) 1978-05-09 US disclosed
US-4062970-A ANIMAL GROWTH PROMOTERS IMC CHEMICAL GROUP, INC. (US) 1977-12-13 US disclosed
US-4051128-A ETHERIFICATION IMC CHEMICAL GROUP, INC. (US) 1977-09-27 US disclosed
US-3960835-A RUMINANT GROWTH PROMOTER COMMERCIAL SOLVENTS CORPORATION (US) 1976-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10239856-B2 Synthesis of resorcylic acid lactones useful as therapeutic agents HSP90AA1, HSP90AB1, HSP90AB2P LMNA 2644/4885SMN1; SMN2 4166/4885ESR2 1670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.